Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898465 | 0.98 | HPGD (0.61) | SIRT2SIRT1ALDH1A1RAB9AHPGD | |
| SCHEMBL28242074 | 0.95 | HPGD (0.61) | SIRT2SIRT1ALDH1A1RAB9AHPGD | |
| SCHEMBL20187714 | 0.94 | HPGD (0.59) | SIRT2SIRT1ALDH1A1RAB9AHPGD | |
| SCHEMBL22015905 | 0.92 | HPGD (0.65) | ALDH1A1RAB9AHPGDNPC1HTT | |
| SCHEMBL20188098 | 0.92 | HPGD (0.65) | ALDH1A1RAB9AHPGDNPC1HTT | |
| SCHEMBL18821718 | 0.92 | RAB9A (0.55) | SIRT2SIRT1ALDH1A1RAB9AHPGD | |
| SCHEMBL14871042 | 0.90 | RAB9A (0.56) | SIRT2SIRT1ALDH1A1RAB9AHPGD | |
| SCHEMBL18821737 | 0.90 | RAB9A (0.56) | SIRT2SIRT1ALDH1A1RAB9AHPGD | |
| SCHEMBL3067260 | 0.86 | ALDH1A1 (0.58) | ALDH1A1RAB9AHPGDHTTSMN1; SMN2 | |
| SCHEMBL4690718 | 0.86 | MEN1 (0.71) | SIRT2SIRT1ALDH1A1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181746-A1 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| EP-3363645-B1 | PRETREATMENT OF UV CURED INK UNDER-LAYERS | XEROX CORP (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3375621-A2 | TWO COMPONENT INK JETTABLE PRIMER AND INCORPORATION OF ADHESION PROMOTER TO THE INK FOR PRINTING ONTO 3D OBJECTS | Xerox Corporation (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3363645-A1 | PRETREATMENT OF UV CURED INK UNDER-LAYERS | Xerox Corporation (US) | 2018-08-22 | — | — | EP | disclosed |
| US-10005294-B1 | Two component ink jettable primer and incorporation of adhesion promoter to the ink for printing onto 3D objects | XEROX CORPORATION (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-9969185-B1 | Pretreatment of UV cured ink under-layers | XEROX CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| US-6342497-B1 | 2″-deoxy hygromycin derivatives | PFIZER INC | 2002-01-29 | — | — | US | disclosed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| CN-1299365-A | Hygromycin A derivatives | PFIZER PROD INC (US) | 2001-06-13 | — | — | CN | disclosed |
| EP-1077984-A1 | 2\"-DEOXY HYGROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1075483-A2 | HYGROMYCIN A DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-14 | — | — | EP | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
| CN-1243505-A | Benzamidine derivatives | AJINOMOTO KK (JP) | 2000-02-02 | — | — | CN | disclosed |
| WO-1999057127-A1 | 2'-DEOXY HYGROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| US-4250315-A | 2-(SUBSTITUTED AMINO-PHENYL), SULFONIC ACID SUBSTITUTED | HOFFMANN-LA ROCHE INC. (US) | 1981-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | SIRT2 35/4885SIRT1 52/4885ALDH1A1 1155/4885 |
| US-20230181746-A1 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | HDAC3, HDAC1, HDAC5 | SIRT2 77/4885SIRT1 73/4885ALDH1A1 1578/4885 |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | SIRT2 1389/4885SIRT1 1175/4885ALDH1A1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.